Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter